The historical data trend for Luye Pharma Group's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group (FRA:LUP) has a Buyback Yield % of 0.00 as of Jul. 10, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Luye Pharma Group and its competitors. According to the industry distribution chart, Luye Pharma Group ranks #999999 out of 291 companies in the Drug Manufacturers industry.
Is Luye Pharma Group's Buyback Yield % too high?
Luye Pharma Group's current Buyback Yield % is 0.00. Based on the distribution chart, Luye Pharma Group ranks #999999 out of 291 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Luye Pharma Group has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #999999 out of 291 companies for Buyback Yield %. This places Luye Pharma Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Luye Pharma Group and its competitors. Luye Pharma Group's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.34, compared to a current price of €0.21 — trading 38.2% below its estimated fair value. The current Buyback Yield % is 0.00. Luye Pharma Group's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current Buyback Yield % is 0.00 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.21 is trading 38.2% below its estimated GF Value™ of €0.34.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for FRA:LUP:
Buyback Yield %: 0.00
GF Value™: €0.34 vs. price of €0.21 (38.2% below fair value)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
46GF Score
Get the complete analysis for FRA:LUP
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
